Zai Lab
Xiao Wang has a diverse work experience in different organizations and roles. They started their career as an Orthopaedic Surgeon at Qingdao Municipal Hospital from June 2006 to September 2008. Later, they worked as a Postdoctoral Researcher at the University of Oxford/Swansea University from October 2012 to October 2013. In 2011, Xiao Wang joined The Johns Hopkins University School of Medicine as an Assistant Professor until March 2022. Currently, they are working at Zai Lab as a Principal Scientist from April 2022 onwards.
Xiao Wang obtained a Doctor of Philosophy (Ph.D.) in Orthopedic Surgery from the University of Oxford from 2008 to 2011. Prior to that, from 2001 to 2008, they earned a Doctor of Medicine (MD) in Orthopaedic Surgery from Hunan College of Traditional Chinese Medicine.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.